Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People treated with Viread, Vemlidy or Baraclude are less likely to develop this malignancy.
This is the first major study to assess an eight-week regimen in people with all genotypes of hep C and compensated cirrhosis.
A large Canadian study found that just 2% of such women developed more severe cirrhosis within one year of delivery.
In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.
Conatus Pharmaceuticals’ study of emricasan for non-alcoholic steatohepatitis found the drug had no significant impact.
Researchers analyzed health data regarding modern hep C treatments specific to New South Wales.
Researchers reached this conclusion after reviewing data on more than 30,000 people.
Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.
Better antiretrovirals have likely mitigated HIV’s effects on the risk of end-stage liver disease and liver cancer in those with hep C.
Researchers followed nearly 10,000 people with hepatitis C, some of whom were treated with direct-acting antivirals.
Indicators of liver health improved at the same rate among those with cirrhosis who were cured of hep C regardless of their HIV status.
Caring for someone with cirrhosis is hard work and much harder when there is hepatic encephalopathy.
Liver disease such as viral hepatitis and other liver conditions can cause damage to the liver which can range from mild to severe.
This is according to an analysis of nearly 5,000 Italians recently treated for the virus.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.